If you’ve been researching how to bring a food ingredient to market in the United States, you’ve likely come across the term “GRAS certification.”
It’s a phrase that sounds official—but it doesn’t actually reflect how the regulatory process works.
The reality is simple: there is no such thing as GRAS certification.
Understanding what GRAS actually is—and how it works—is critical for avoiding regulatory risk, delays, and costly missteps when commercializing an ingredient.
GRAS stands for “Generally Recognized as Safe.” It is a regulatory designation used by the U.S. Food and Drug Administration (FDA) to indicate that a substance is considered safe for its intended use in food.
Unlike formal approvals, GRAS is not granted as a certificate or license. Instead, it is a scientific and regulatory conclusion based on:
When people refer to “GRAS certification,” what they’re usually thinking of is a GRAS determination or GRAS affirmation—both of which involve evaluating safety through scientific evidence, not receiving a formal approval.
The term creates the impression that there is a governing body issuing approvals or certificates for ingredients.
In practice:
Instead, companies are responsible for establishing and supporting their own GRAS conclusions using credible scientific evidence.
Treating GRAS like a simple certification process can lead to underestimating the level of rigor required—and increase the risk of regulatory or commercial issues down the line.
While there is no certification, there are two recognized pathways to establishing GRAS status. Both rely on the same scientific foundation and require a robust, well-documented safety evaluation.
In both pathways, a GRAS conclusion is supported by:
For novel or complex ingredients, additional studies may be needed to support a defensible conclusion.
The key difference lies in how the conclusion is finalized:
A company reaches a GRAS conclusion independently, typically with support from an external panel of qualified experts who evaluate the available data and confirm that the safety conclusion is generally recognized. The conclusion is documented but not submitted to the FDA.
The FDA is not directly involved, but the conclusion must still meet the same scientific and regulatory standards.
A company submits its GRAS conclusion and supporting dossier to the FDA for review. The FDA evaluates whether the notice provides a sufficient basis for a GRAS conclusion. The scientific content of the submission is the same as that used in a self-affirmed GRAS, but it undergoes FDA review.
Following its evaluation, the FDA may respond in one of several ways:
A “no questions” letter is often perceived as an approval, but it is not a formal authorization or certification; it reflects the FDA’s position based on the information provided.
GRAS is often approached as a regulatory requirement—but it plays a much larger role in product success.
A well-supported GRAS determination can:
A weak or incomplete approach, on the other hand, can:
This is why GRAS should be approached as a strategic decision, not just a submission.
GRAS is not appropriate for every ingredient.
Depending on the substance and intended use, alternative pathways may be required, including:
Selecting the correct pathway early is essential to avoiding compliance issues and unnecessary delays.
Establishing GRAS status demonstrates safety—but in many cases, companies go further to strengthen their position in the market.
This may include:
This broader approach helps support not just regulatory acceptance, but long-term commercial success.
While “GRAS certification” is a familiar phrase, it doesn’t reflect how the process actually works.
GRAS is not something you receive—it’s something you establish and defend through science, evidence, and expert evaluation.
Whether you’re evaluating GRAS feasibility, preparing a dossier, or determining the right regulatory pathway for your ingredient, dicentra can help you move forward with confidence.
Talk to our team about your GRAS strategy →